Merck KGaA (MKKGY)

OTCMKTS · Delayed Price · Currency is USD
27.95
+0.11 (0.40%)
May 12, 2025, 3:59 PM EDT
-16.47%
Market Cap 60.51B
Revenue (ttm) 21.90B
Net Income (ttm) 2.88B
Shares Out n/a
EPS (ttm) 6.61
PE Ratio 21.05
Forward PE 13.99
Dividend 0.34 (1.22%)
Ex-Dividend Date Apr 29, 2025
Volume 21,825
Average Volume 115,645
Open 27.83
Previous Close 27.84
Day's Range 27.69 - 28.16
52-Week Range 24.32 - 39.17
Beta 0.64
RSI 52.70
Earnings Date May 15, 2025

About Merck KGaA

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing a... [Read more]

Sector Healthcare
Founded 1668
Employees 59,020
Stock Exchange OTCMKTS
Ticker Symbol MKKGY
Full Company Profile

Financial Performance

In 2024, Merck KGaA's revenue was 21.16 billion, an increase of 0.78% compared to the previous year's 20.99 billion. Earnings were 2.78 billion, a decrease of -1.66%.

Financial numbers in EUR Financial Statements

News

Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer treatments...

14 days ago - Investopedia

Wall Street Breakfast Podcast: Huawei Preps AI Chip To Challenge Nvidia: Report

Huawei preparing to test latest AI chip to challenge Nvidia (NVDA): report. Merck KGaA to buy Springworks for $3.9 billion. CrowdStrike unveils new AI agents for cybersecurity.

14 days ago - Seeking Alpha

Santé : Merck KGaA acquiert l'américain SpringWorks Therapeutics pour 3,4 milliards de dollars

Le groupe de santé allemand Merck KGaA a annoncé lundi l'achat de la société biopharmaceutique américaine SpringWorks Therapeutics, spécialisée...

14 days ago - Le Figaro

Merck KGaA (MKGAF) to Acquire SpringWorks Therapeutics for $3.9 Billion

Merck KGaA (MKGAF) to Acquire SpringWorks Therapeutics for $3.9 Billion

14 days ago - GuruFocus

Merck KGaA to Acquire SpringWorks Therapeutics for $3.9 Billion | SWTX stock news

Merck KGaA to Acquire SpringWorks Therapeutics for $3.9 Billion | SWTX stock news

14 days ago - GuruFocus

Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to ...

Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business | SWTX Stock News

14 days ago - GuruFocus

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable ...

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business | SWTX Stock News

14 days ago - GuruFocus

Germany's Merck Set to Buy SpringWorks in $3.9 Billion Deal

The deal to acquire the U.S. biopharmaceutical company confirms an earlier report in The Wall Street Journal.

15 days ago - WSJ

Germany's Merck KGaA in $3.9 bln deal to acquire US biotech firm SpringWorks

German healthcare and materials group Merck KGaA said on Monday it struck a deal to acquire U.S. biotech firm SpringWorks Therapeutics for an equity value of $3.9 billion to boost its cancer drug busi...

15 days ago - Reuters

Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add r...

15 days ago - GlobeNewsWire

Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a Stamford, Connecticut-bas...

15 days ago - Business Wire

Germany's Merck nears roughly $3.5 billion deal for SpringWorks, WSJ reports

Germany's Merck KGaA is nearing a roughly $3.5 billion deal for SpringWorks Therapeutics , the Wall Street Journal reported on Thursday, citing people familiar with the matter.

18 days ago - Reuters

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks

The two companies have been talking for months about a deal

18 days ago - WSJ

Curiosity Cube 2025: MilliporeSigma’s Mobile Science Labs Tour Globally to Bring STEM Education to Students

Curiosity Cube tours North America, Europe, and for the first time, Africa Mobile science lab aims to reach 60,000 students in 19 countries Interactive lessons on artificial intelligence designed to s...

18 days ago - Financial Post

Merck KGaA: Still A Bit Too Expensive

Merck KGaA's stock remains a 'hold' due to its high valuation, trading at an earnings multiple of around 20 and a 4.5% free cash flow yield. Read why MKGAF is a hold.

2 months ago - Seeking Alpha

Resilience is part of our DNA, says Merck KGaA CEO

Belén Garijo, CEO of Merck KGaA, said the German pharmaceutical company has increased its readiness to deal with the ongoing geopolitical uncertainty, and is confident it will continue delivering prof...

2 months ago - CNBC International TV

Merck KGaA (MKGAF) Q4 2024 Earnings Call Transcript

Merck KGaA (OTCPK:MKGAF) Q4 2024 Results Conference Call March 6, 2025 8:00 AM ET Company Participants Florian Schraeder - Head of Investor Relations Belen Garijo - Group CEO Helene von Roeder - Group...

2 months ago - Seeking Alpha

Merck KGaA sees forex-adjusted earnings growth of up to 8% this year

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor chemicals and for lab equipment in biotech drug production.

2 months ago - Reuters

Merck KGaA to replace two executives with company veterans

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new leadership from June but it added that its strategy remains unchanged.

2 months ago - Reuters

Exclusive: Germany's Merck KGaA in talks to buy US cancer biotech firm Springworks, sources say

Merck KGaA , the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics , according to people familiar with the matter...

3 months ago - Reuters

Merck KGaA says high asset prices call for prudent M&A approach

The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.

3 months ago - Reuters

Mirror Biologics Enters Clinical Collaboration with Merck KGaA, Darmstadt, Germany in Metastatic Colorectal Cancer

TAMPA, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Mirror Biologics, Inc., specializing in development and manufacturing of immunotherapy products where the active ingredient is living, non-genetically al...

4 months ago - GlobeNewsWire